IDH1 and acute myeloid leukemia: A phase 1/2, Multicenter, Open-label study of FT-2102 as a single agent and in combination with azacitidine or cytarabine in patients with acute myeloid leukemia or myelodysplastic syndrome with an IDH1 mutation